



Investor Presentation

June 2024



Forward Looking Statements

- This presentation (“Presentation”) is for informational purposes only to assist interested parties in making an evaluation with respect to a proposed business combination and related transactions (collectively, the “Business Combination”) between SEP Acquisition Corp. (“SEPA”) and SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”).

- This Presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Business Combination or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any securities of SEPA, SANUWAVE, or any of their respective affiliates. You should not construe the contents of this Presentation as legal, tax, accounting or investment advice or a recommendation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision.

- ***Projections***

- The financial projections presented in this Presentation represent management’s current estimates of future performance based on various assumptions, which may or may not prove to be correct. The Company’s independent registered public accounting firm has not audited, reviewed, compiled or performed any procedure with respect to the projections, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto. These projection should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying these projections are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks that could cause actual results to differ materially from those contained in these projections. Accordingly, there can be no assurance that the projections will be realized.

- ***Use of Data***

- The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. SEPA and the Company assume no obligation to update the information in this presentation.

- ***Trademarks***

- SEPA and the Company own or have rights to various trademarks, service marks and trade names that they use in connection with the operation of their respective businesses. This presentation may also contain trademarks, service marks, trade names and copyrights of third parties, which are the property of their respective owners. The use or display of third parties’ trademarks, service marks, trade names or products in this Presentation is not intended to, and does not imply, a relationship with SEPA or the Company, or an endorsement or sponsorship by or of SEPA or the Company.

- ***Forward-Looking Statements***

- This Presentation may contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. SANUWAVE’s and SEPA’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “might” and “continues,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements may include, without limitation, the satisfaction of the closing conditions to the Business Combination, the timing of the closing of the Business Combination and expected results for the combined Company. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of SANUWAVE and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; (2) the inability to consummate the Business Combination, including due to any failure to obtain approval of the stockholders of SANUWAVE or SEPA or other conditions to closing in the merger agreement, such as the requirements that (i) SANUWAVE obtain the approval of the holders of 80% of its outstanding convertible promissory notes and warrants to convert such securities into shares of SANUWAVE’s common stock immediately prior to the closing and (ii) SEPA shall have at least \$12.0 million at closing resulting from proceeds of (a) SEPA’s Class A common stock that has not been redeemed and (b) a private placement; (3) delays in obtaining or the inability to obtain any necessary regulatory approvals required to complete the Business Combination; (4) the inability to obtain or maintain the listing of SEPA’s securities on Nasdaq following the Business Combination; (5) costs related to the Business Combination; (6) changes in applicable laws or regulations; (7) the possibility that SANUWAVE or SEPA may be adversely affected by other economic, business, and/or competitive factors; and (8) other risks and uncertainties to be identified in the registration statement/proxy statement (when available) relating to the Business Combination, including those under “Risk Factors” therein, and in other filings with the Securities and Exchange Commission (the “SEC”) made by SANUWAVE and SEPA. SANUWAVE and SEPA caution that the foregoing list of factors is not exclusive, and caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither SANUWAVE nor SEPA undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law.

- Readers are referred to the most recent reports filed with the SEC by SANUWAVE. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and SANUWAVE undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

- ***Important Information About the Transactions and Where to Find It***

- SANUWAVE and SEPA will file relevant materials with the SEC, including a Form S-4 registration statement to be filed by SEPA, which will include a prospectus with respect to SEPA’s securities to be issued in connection with the proposed Business Combination and a proxy statement with respect to SEPA’s stockholder meeting at which SEPA’s stockholders will be asked to vote on the proposed Business Combination and related matters. In addition, SANUWAVE will file a proxy statement with respect to SANUWAVE’s stockholder meeting at which SANUWAVE’s stockholders will be asked to vote on the proposed Business Combination and related matters. SANUWAVE’S stockholders and other interested persons are advised to read, when available, the Form S-4 and the amendments thereto, the proxy statement and other information filed with the SEC in connection with the Business Combination, as these materials will contain important information about SANUWAVE, SEPA and the Business Combination. When available, the proxy statement and other relevant materials for the Business Combination will be mailed to stockholders of SANUWAVE as of a record date to be established for voting on the proposed Business Combination and related matters. The preliminary Form S-4 registration statement and preliminary proxy statements, the final Form S-4 registration statement and definitive proxy statements and other relevant materials in connection with the Business Combination (when they become available), and any other documents filed by SANUWAVE with the SEC, may be obtained free of charge at the SEC’s website (www.sec.gov). SANUWAVE’s stockholders will also be able to obtain a copy of such documents, without charge, by directing a request to SANUWAVE at 11495 Valley View Road, Eden Prairie, Minnesota 55344.



Investment Highlights



1

Rapidly growing **commercial stage** medical device company in the **\$45 billion** US wound care space. FDA approved. Schedule 1 CMS reimbursement.

2

Wound care is undergoing a **major transition to evidence based medicine**. Re-imburement being restructured around efficacy and cost-effectiveness. Need to align the interests of **patients, physicians, and payors**. This favors SANUWAVE directed energy products.

3

Backed by **strong, broad IP portfolio** (over 165 patents). Foundational patents in the space as well as use patents with applications both in and outside wound care.

4

Attractive financial profile: high gross margin business (73%) with 55-65% of revenues from consumables stream. Company achieved **Positive Operating Income** and Adjusted EBITDA in Q4 2023. Company grew revenues +53% yoy in Q1 (Mar) 2024.

Full year 2024 revenue guidance of **50% growth** vs 2023 (**\$30+ million** in 2024 revenues)



Market Opportunity

Growth Drivers

- Centers for Medicare and Medicaid Services (CMS) and commercial providers increasingly classifying regenerative technology products as medically necessary
- Aging** population
- Increase in obesity, diabetes, cancers and autoimmune disorders
- Trend to move “care to the edge” and away from hospital settings

~\$18 Billion

Venous Leg Ulcers (VLUs)²
Annual treatment costs
Inpatient only, all payors

~\$12 Billion

Pressure Ulcers (PUs)³
Annual treatment costs
Inpatient only, all payors

**Targeting a
~\$45 Billion Market
in the US**

Estimated Annual Wound Care
Costs in the United States

~\$15 Billion

Diabetic Foot Ulcers (DFUs)¹
Annual treatment costs
All care settings, all payors

Treatment Opportunity in the U.S.

2,200

Wound care
centers

10,000

Physician offices

15,000

Skilled nursing
facilities

28,900

Assisted living
facilities

1) Rice et al. Diabetes care 2014;37.

2) 651-658. 2Rice et. al J Med Econ 2014;17 (5): 347-356.

3) National Pressure Ulcer Advisory Panel (NPUAP).



UltraMIST[®] Therapy System

- A low-frequency, non-contact ultrasound energy delivered through a fluid mist
- Device never touches the wound surface. Treatment is pain-free
- Reduces wound size and speeds healing¹
- Reduces ongoing pain²
- Promotes wound healing below the surface by modulating cell membranes to drive increased blood flow and capillary formation
- Kills bacteria by lysing cell walls
- 3 to 20 minute treatment time with simple, self-contained system
- Highly portable: weighs only 7 pounds

Durable device, consumable applicator: one per procedure.

Indications for use

FDA Approved

- Diabetic Foot Ulcers
- Pressure Ulcers
- Venous Leg Ulcers
- Deep Tissue Pressure Injuries
- Surgical Wounds



1. [Ultrasound therapy for recalcitrant diabetic foot ulcers: results of a randomized, double-blind, controlled, multicenter study](#)
 2. [15. A Prospective, Randomized, Controlled Trial Comparing the Effects of Noncontact, Low-frequency Ultrasound to Standard Care in Healing Venous Leg Ulcers](#)


Transition to Evidence Based Medicine

- Concerns about the efficacy of several common treatment practices such as skin substitutes, grafts, and hyperbaric have led to payor reassessment of reimbursement

In meta study (Driver et al) non-contact low frequency ultrasound showed 72% greater healing rate at 12 weeks than standard of care¹

- Reducing or terminating reimbursement for numerous modalities
- Increased reimbursement for energy-based treatments
- UltraMIST is one of only two only energy products that currently qualify for a schedule one code for woundcare
- To change a category, a product must **align the needs of patients, physicians, and payors.**

The Wound Care Market is Transitioning to Evidence Based Medicine



1. "Noncontact low-frequency ultrasound therapy in the treatment of chronic wounds: A meta-analysis," 2011 Driver et al



Payor Economics Driven by Patient Benefit

Cost to close wound in hospital:

Energy: \$4,500¹

vs

Skin Substitutes: \$14.3k¹

Heal time: 16 weeks drops to 8.2 weeks


Recurrence:

~50% of Diabetic Foot Ulcers recur with standard of care.

Revascularization resulting from energy treatment may represent a cure, not just symptom relief.

Wound/Ulcer Progression from Deep Tissue Injury in ICU

UltraMIST vs Standard of Care



Stage 2: partial dermal thickness

Stage 3: full dermal thickness

Stage 4: visible bone, muscle, tendon

Unstageable: full thickness obscured with slough and/or eschar

SDTI: severe sub dermal wound without surface opening


1. Per CMS prices at 8.2 week treatment time

2. Graphic from "Effects of non contact low-frequency ultrasound on healing of suspected deep tissue injury: a retrospective analysis" Jeremy S Honaker et al; Int wound J 2012



Physician Economics

UltraMIST



Schedule 1: Reimbursed under CPT code 97610: “low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day”

Extremely limited code as nearly all ultrasound devices are contact

Reimbursement = \$400-700/procedure in physician office

- 100% Medicare reimbursement, significant private

Consumable costs = ~\$100/procedure (list price)

Can be used by Nurse Practitioner

3 to 20 minute treatment time

~85 procedures to pay for device

Unit Economics

Classic “Razor/Razorblade” model



UltraMIST	
System	
Price	\$35,000
Applicators	
Single Use	
Price	\$100

** Pricing reflects manufacturer's suggested retail price (MSRP)*

TOTAL
ESTIMATED GROSS
MARGIN:

75%




Manufacturing

Moving to dual source contract manufacturers for UltraMIST device: Production, Summer 2024



Lower cost, better supply chain management
Capacity to ~70 systems a month in first stage

Redesign of Applicators to enhance manufacturability: Production in late Q4 2024



New four cavity molds: easier assembly, better quality, lower cost

Consumables Capacity

- **6,000** applicators/wk in June 2023
- **9,600** applicators/wk in May 2024
- **~24,000** applicators/wk by December 2025

Significant upside to Gross Margins from cost reductions




UltraMIST now over 95% of Sanuwave Revenues

Fundamentally a Consumables Model

More units in field X Higher usage rates X Higher consumable pricing = Rapid growth in recurring revenue

Continuous UltraMIST revenue growth throughout 2023. Strong year on year growth in Q1 2024.



Active UltraMIST Systems in Use (Future Targets, End of Period)

Q4 2023A	Q1 2024A	CY 2024E	CY 2025E
666	709	1,000+	2,000+

709

Active Systems* in the field at end Q1

43

Systems sold in Q1 2024 (vs 28 in Q1 2023 and 79 in Q4 2023)

*Active systems defined as customers who have ordered consumables in prior 6 months



Rapid Growth in Revenue

Q4 2023



- **Revenue:**
\$7.0M + 27% YoY
- **Operating Income:**
\$1.0M
- **Adj EBITDA:**
+\$662k

Q1 2024

(Seasonally slowest quarter)



- **Revenue:**
\$5.8M + 53% YoY
- **Operating Income:**
\$-1.1M
- **Adj EBITDA:**
-\$59k

Q2 Guidance



- **Revenue:**
+45-55% growth v Q2 2023
(\$6.75M to \$7.25M)
- Gross Margin: mid 70%'s

2024 Guidance



- **Revenue:**
+50% revenue growth vs
2023
(\$30M+ revs vs \$20.1M in 2023)

Summary

Wound care is undergoing a **payor led shift to evidence based medicine and reimbursement.**

This has aligned incentives for Patients, Payors, and Providers.

SANUWAVE is in a prime position to benefit:

- Approved products protected by broad IP
- Strong existing reimbursement with room to improve
- Experienced, focused sales force
- Ability to meet demand with expanded manufacturing



Rapid growth poised to accelerate and bring company to **profitability.**



Management Team

Morgan C. Frank

[CEO/Chairman](#)

Morgan C. Frank joined SANUWAVE as chairman of the board of directors in August of 2022 and became CEO in May 2023. Mr. Frank has been a principal at the life sciences focused investment fund Manchester Management since 2003 and a director of Manchester Explorer Cayman Ltd since 2013. Prior to that, he was a founder and managing director at First Principles Group, a boutique consultancy and principal investor specializing in corporate restructuring, restarts, intellectual property assessment and salvage, and spin-outs. Prior, Mr. Frank spent approximately five years as an analyst and portfolio manager at Hollis Capital, a San Francisco-based hedge fund. He currently sits on the board of directors of Modular Medical (Nasdaq: MODD), a development-stage insulin delivery company. Mr. Frank holds BA's in Economics and in Political Science from Brown University.

Andrew Walko

[President](#)

Andrew Walko joined SANUWAVE as President in July of 2023 and brings over 17 years of progressive leadership experience in the medical device industry and the US Army. Andrew held key leadership roles at Biomerics Advanced Catheter, Minnetronix Medical and Greatbatch/Integer where he focused on operations, new product scale-up and launch, and cost improvement initiatives before joining SANUWAVE. In addition to his medical device experience, Andrew served in the US Army and graduated from the US Army Ranger School. He has deployed to Iraq, Afghanistan, and Haiti. He is also actively engaged with the Leukemia and Lymphoma Society and has served as the Executive Challenge Chair and the Corporate Walk Chair for the Light the Night event in the Twin Cities. Andrew has a Bachelor's Degree in Business Management from West Virginia University and an MBA from the University of Minnesota.

Peter Stegagno

[COO](#)

Peter Stegagno joined SANUWAVE as Vice President, Operations in March 2006. Stegagno has nearly 30 years of experience in the medical device market, encompassing manufacturing, design and development, quality assurance and international, and domestic regulatory affairs. He has been instrumental in the development and deployment of international operational processes for leading medical device companies. Prior to joining SANUWAVE, Stegagno served as Vice President of Quality and Regulatory Affairs for Elekta and director level roles in medical device companies including Genzyme Biosurgery. Before focusing on the medical field, he enjoyed a successful career in production roles in the space industry, including avionics guidance systems for military applications and control computers for the space shuttle. Stegagno graduated from Tufts University with a B.S. degree in Chemical Engineering

Peter Sorensen

[Chief Financial Officer](#)

Peter Sorensen joined SANUWAVE as Chief Financial Officer in April of 2024 and brings over a decade of finance experience including the medical device industry since 2017. Peter was most recently the Vice President of Finance and Human Resources at Endogenex, Inc., a venture-backed medical device company focused on the treatment of type-2 diabetes. Prior to Endogenex, he spent time at LivaNova PLC in the new ventures group with the Transcatheter Mitral Valve Replacement and Vagus Nerve Stimulation for Heart Failure divisions. He also spent time in consulting at eCapital Advisors implementing FP&A solutions for large public and private companies. Sorensen brings strong finance, forecasting, analysis, and capital markets experience as well as abilities in software, process automation, and human resources to SANUWAVE. Sorensen earned his bachelor's degree from Bethel University and his Master of Business Administration from St. Cloud State University.

Tim Hendricks

[Executive Vice President of Sales – U.S. Wound](#)

Tim Hendricks joined Sanuwave in February of 2023 as the Executive V.P. of Sales for the U.S. Wound business. Across his 20 years of industry experience, Hendricks has taken on progressive roles in sales leadership, training & development, and professional education with responsibilities both internationally and in the U.S.

Tim has led sales and sales leadership teams in medical devices, biologics, specialty pharmaceuticals, and durable medical equipment. His passion for collaboration and growth has allowed him to thrive at start-ups and Fortune 500 companies such as Boston Scientific (formerly Advanced Bionics), Smith & Nephew (formerly Osiris Therapeutics), and most recently Byram Healthcare as the Vice President of Sales.

Having spent a decade working in the chronic wound market, Hendricks will continue the build-out of Sanuwave's team and growth strategy. He earned a Bachelor of the Arts in Advertising from Southern Methodist University.

Nanci Gilmore

[Vice President, Commercial Operations](#)

Nanci Gilmore joined SANUWAVE in February 2023 as the Vice President of Commercial Operations. Gilmore has over 25 years of progressive experience in the medical device industry, specifically focusing on start-up, rapid-growth enterprises. Gilmore's passion and commitment to bringing innovative technologies to clinicians, with a patient-centric mindset, results in high-yield, consumer program development and implementation. Gilmore's diverse experience spans multiple medical specialties, representing organizations including Entellus Medical, SenoRx, Echosens, and most recently, THINK Surgical.

Gilmore earned her bachelor's degree from Clark University and her master's degree from the University of North Carolina at Chapel Hill




Appendix



Advanced Wound Care Continuum

ACUTE WOUND CARE

CHRONIC / ADVANCED WOUND CARE



SANUWAVE's ENERGY FIRST products added to standard of care.



Intellectual Property

165+ patents including broad foundational patents in technology for forming penetrating shockwaves and in medical use cases.

Cover reflector/electrode commination and structure and application to wounds, lungs, bacterial cleansing, and other applications including software, personalized treatment algorithms, and direct consumables links to billing.

